Repare Therapeutics Inc. , a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib in combination with FOLFIRI for the.
Some oncologists have called the regimen a new standard of care, while others aren't convinced that the new first-line pancreatic cancer regimen is worth the high cost.
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.